📣 VC round data is live. Check it out!

Phreesia Valuation Multiples

Discover revenue and EBITDA valuation multiples for Phreesia and similar public comparables like Heren Health, Echo IQ, GPI Group, Veradigm and more.

Phreesia Overview

About Phreesia

Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.


Founded

2005

HQ

United States

Employees

2.1K

Financials (LTM)

Revenue: $491M
EBITDA: $109M

EV

$562M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Phreesia Financials

Phreesia reported last 12-month revenue of $491M and EBITDA of $109M.

In the same LTM period, Phreesia generated $403M in gross profit, $109M in EBITDA, and $6M in net income.

Revenue (LTM)


Phreesia P&L

In the most recent fiscal year, Phreesia reported revenue of $481M and EBITDA of $102M.

Phreesia is profitable as of last fiscal year, with gross margin of 68%, EBITDA margin of 21%, and net margin of 0%.

See analyst estimates for Phreesia
LTMLast FY202320242025202620272028
Revenue$491M$481M$350M$415M$476M
Gross Profit$403M$326M$227M$280M$323M
Gross Margin82%68%65%68%68%
EBITDA$109M$102M($108M)($32M)$25M
EBITDA Margin22%21%(31%)(8%)5%
EBIT Margin0%(1%)(40%)(16%)(2%)
Net Profit$6M$2M($140M)($65M)($3M)
Net Margin1%0%(40%)(16%)(1%)
Net Debt—$19M———

Financial data powered by Morningstar, Inc.

Phreesia Stock Performance

Phreesia has current market cap of $533M, and enterprise value of $562M.

Market Cap Evolution


Phreesia's stock price is $8.77.

Phreesia share price decreased by 4.8% in the last 30 days, and by 64.2% in the last year.

Phreesia has an EPS (earnings per share) of $0.04.

See more trading valuation data for Phreesia
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$562M$533M-4.6%-4.8%-28.9%-64.2%$0.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Phreesia Valuation Multiples

Phreesia trades at 1.1x EV/Revenue multiple, and 5.1x EV/EBITDA.

See NTM and 2027E valuation multiples for Phreesia

EV / Revenue (LTM)


Phreesia Financial Valuation Multiples

As of May 15, 2026, Phreesia has market cap of $533M and EV of $562M.

Phreesia has a P/E ratio of 86.1x.

LTMLast FY202320242025202620272028
EV/Revenue1.1x1.2x1.6x1.4x1.2x
EV/EBITDA5.1x5.5x(5.2x)(17.5x)22.6x
EV/EBITn/m(85.0x)(4.0x)(8.7x)(51.5x)
EV/Gross Profit1.4x1.7x2.5x2.0x1.7x
P/E86.1x231.1x(3.8x)(8.2x)(192.8x)
EV/FCF8.8x9.7x(9.0x)199.7x11.1x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Phreesia Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Phreesia Margins & Growth Rates

Phreesia grew revenue by 7% and EBITDA by 27% in the last fiscal year.

In the most recent fiscal year, Phreesia reported gross margin of 68%, EBITDA margin of 21%, and net margin of 0%.

See estimated margins and future growth rates for Phreesia

Phreesia Margins

Last FY202420252026202720282029
Gross Margin68%68%68%81%
EBITDA Margin21%(8%)5%24%
EBIT Margin(1%)(16%)(2%)4%
Net Margin0%(16%)(1%)3%
FCF Margin12%1%11%15%

Phreesia Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth7%18%15%8%
Gross Profit Growth30%23%15%29%
EBITDA Growth27%(70%)(177%)385%
EBIT Growth(457%)(54%)(83%)(293%)
Net Profit Growth591%(54%)(96%)(635%)
FCF Growth34%(105%)1699%50%

Data powered by FactSet, Inc. and Morningstar, Inc.

Phreesia Operational KPIs

Phreesia's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Phreesia's Rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Phreesia's Rule of X is 43% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Phreesia
LTMLast FY202320242025202620272028
Rule of 4029%31%———
Bessemer Rule of X39%43%———
Revenue per Employee—$0.2M———
Opex per Employee—$0.2M———
S&M Expenses to Revenue18%21%42%30%21%
G&A Expenses to Revenue12%17%23%19%17%
R&D Expenses to Revenue22%25%32%28%25%
Opex to Revenue—69%105%83%70%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Phreesia Competitors

Phreesia competitors include Heren Health, Echo IQ, GPI Group, Veradigm, Artrya, Goodwill E-Health Info, Guiyang Longmaster, Beijing Sunwayworld, Medley Inc. and Equasens.

Most Phreesia public comparables operate across Healthcare Software, EHR & Practice Management, B2B SaaS, Vertical SaaS and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Heren Health7.3x—39.1x—
Echo IQ7383.8x772.5x(127.7x)(127.4x)
GPI Group1.4x1.4x6.8x6.6x
Veradigm—0.5x—3.4x
Artrya26000.0x189.8x(54.8x)(38.3x)
Goodwill E-Health Info8.5x7.9x(14.9x)(20.6x)
Guiyang Longmaster12.6x—100.2x—
Beijing Sunwayworld7.4x—127.7x—

This data is available for Pro users. Sign up to see all Phreesia competitors and their valuation data.

Start Free Trial

Phreesia Funding History

Before going public, Phreesia raised $47M in total equity funding, across 2 rounds.


Phreesia Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-17Undisclosed stage—$17M—Phreesia is a SaaS-focused healthcare technology company that specializes in patient check-in and payment collection solutions for medical practices. The company's core offering includes automated patient check-in software that enables secure, efficient patient information collection and payment processing at the point of care. In November 2017, Phreesia closed a funding round that raised approximately $17 million to continue expanding its market presence and technological advancements; however, the post-money valuation for this round was not publicly disclosed. For the fiscal year ended January 31, 2019, Phreesia reported total revenue of $100.0 million, growing from $79.8 million in the prior fiscal year, with revenue generated from both subscription and related services as well as payment processing fees. The company had not yet reached profitability at the time of the funding round, reporting operating and net losses in its pre-IPO period.
Oct-14Undisclosed stageAscension Ventures; HLM Venture Partners; LLR Partners$30M—Phreesia, a leading healthcare point-of-service platform, secured a $30 million investment on October 23, 2014, led by LLR Partners, with participation from existing investors HLM Venture Partners and Ascension Ventures. The funding aimed to support rapid growth, accelerate product development, and expand its customer base nationwide. Phreesia provides innovative SaaS solutions for patient registration, intake, payments, clinical documentation, and targeted communications, helping healthcare practices improve care delivery and profitability. LLR Partners, a private equity firm focused on middle-market growth companies in sectors including healthcare services and software, highlighted Phreesia's high-growth potential and dynamic management team under CEO Chaim Indig. The investment was advised by Goodwin Procter LLP and Robert W. Baird & Co. Phreesia positioned itself to disrupt healthcare norms by integrating efficiency-driving solutions. The company continued raising capital in subsequent rounds, including $34 million in late 2017 led by Echo Health Ventures, and later pursued an IPO.

Phreesia M&A Activity

Phreesia has acquired 5 companies to date.

Last acquisition by Phreesia was on September 4th 2025. Phreesia acquired AccessOne for $160M (EV/Revenue multiple of ).

See M&A valuation multiples

Latest Acquisitions by Phreesia

AccessOne
Access eforms
MediFind
Insignia Health
Description
AccessOne is a healthcare fintech firm delivering patient financing and payment platforms. It integrates with electronic health records like Epic and Cerner for automated billing, installment plans, and self-service portals. Chicago-based AccessOne processes payments through ACH, credit cards, and text reminders, supporting hospitals and providers with real-time eligibility checks and analytics dashboards.
Access eForms is a forms automation solution for healthcare organizations streamlining paperless processes. Louisville-based since 2003, it deploys across hospitals and IDNs with integrations to EHRs like Epic and Cerner. Serving hundreds of facilities worldwide, the platform enables mobile access for admissions, HR, and finance forms, ensuring HIPAA compliance. Access eForms supports over 1,000 form templates, reducing printing by 90% in deployed sites.
MediFind is a healthcare technology platform based in New York City. It leverages AI to identify global medical experts from 2.5 million physicians across datasets for conditions ranging from rare diseases to cancer. Founded from technology used by Roche for 18 years, MediFind delivers expert finder, second opinions, clinical trial matching, and research summaries from 100,000 monthly publications. The platform serves patients, pharma firms, and hospitals in the United States and Europe.
Insignia Health is a Portland, Oregon-based company providing the Patient Activation Measure assessment tool. The platform quantifies patient engagement levels to guide interventions in healthcare delivery. Adopted by providers like Kaiser Permanente and Humana, it integrates with EHR systems to personalize care plans and reduce costs.
HQ CountryUnited StatesBrazilUnited StatesUnited States
HQ City
Charlotte, SC
Belo Horizonte
Philadelphia, PA
Portland, OR
Deal Date4 Sep 202514 Aug 202314 Jul 202313 Dec 2021
Valuation$160M$38M$9M$34M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Phreesia acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Phreesia

When was Phreesia founded?Phreesia was founded in 2005.
Where is Phreesia headquartered?Phreesia is headquartered in United States.
How many employees does Phreesia have?As of today, Phreesia has over 2K employees.
Who is the CEO of Phreesia?Phreesia's CEO is Chaim Indig.
Is Phreesia publicly listed?Yes, Phreesia is a public company listed on NYSE.
What is the stock symbol of Phreesia?Phreesia trades under PHR ticker.
When did Phreesia go public?Phreesia went public in 2019.
Who are competitors of Phreesia?Phreesia main competitors include Heren Health, Echo IQ, GPI Group, Veradigm, Artrya, Goodwill E-Health Info, Guiyang Longmaster, Beijing Sunwayworld, Medley Inc., Equasens.
What is the current market cap of Phreesia?Phreesia's current market cap is $533M.
What is the current revenue of Phreesia?Phreesia's last 12 months revenue is $491M.
What is the current revenue growth of Phreesia?Phreesia revenue growth (NTM/LTM) is 7%.
What is the current EV/Revenue multiple of Phreesia?Current revenue multiple of Phreesia is 1.1x.
Is Phreesia profitable?Yes, Phreesia is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Phreesia?Phreesia's last 12 months EBITDA is $109M.
What is Phreesia's EBITDA margin?Phreesia's last 12 months EBITDA margin is 22%.
What is the current EV/EBITDA multiple of Phreesia?Current EBITDA multiple of Phreesia is 5.1x.
What is the current FCF of Phreesia?Phreesia's last 12 months FCF is $64M.
What is Phreesia's FCF margin?Phreesia's last 12 months FCF margin is 13%.
What is the current EV/FCF multiple of Phreesia?Current FCF multiple of Phreesia is 8.8x.
How many companies Phreesia has acquired to date?As of May 2026, Phreesia has acquired 5 companies.
What was the largest acquisition by Phreesia?$160M acquisition of AccessOne on 4th September 2025 was the largest M&A Phreesia has done to date.
What companies Phreesia acquired?Phreesia acquired AccessOne, Access eforms, Insignia Health, MediFind, and Vital Score Health (now Phreesia).
In how many companies Phreesia has invested to date?Phreesia hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Phreesia

Lists including Phreesia

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial